XML 59 R50.htm IDEA: XBRL DOCUMENT v3.19.3
Collaboration and License Agreements - CStone Pharmaceuticals Purchase Agreement (Details) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Jun. 30, 2018
Sep. 30, 2019
Sep. 30, 2018
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Remaining unsatisfied performance obligation   $ 70,800,000     $ 70,800,000  
Revenue   26,024,000 $ 15,198,000   82,472,000 $ 64,374,000
Milestones achieved   0 0   0 0
Collaboration revenue – related party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue   5,516,000 8,732,000   32,414,000 42,478,000
Milestones achieved       $ 15,000,000.0    
Royalty revenue – related party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue   2,666,000 $ 2,001,000   7,569,000 $ 4,991,000
CStone Pharmaceuticals | CStone Agreement            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Initial payment received $ 12,000,000.0          
Potential future milestone payments   5,000,000.0     5,000,000.0  
Remaining unsatisfied performance obligation   500,000     500,000  
Milestones achieved   0        
CStone Pharmaceuticals | CStone Agreement | Minimum            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Royalty percentage 15.00%          
CStone Pharmaceuticals | CStone Agreement | Maximum            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Potential future milestone payments   $ 412,000,000.0     412,000,000.0  
Royalty percentage 19.00%          
CStone Pharmaceuticals | CStone Agreement | Royalty revenue – related party            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Revenue         $ 0